Clinical Research Directory

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

Sponsor: Novartis Pharmaceuticals

Summary

This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.

Official title: Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel

Key Details

Conditions